PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS

PR&P 由美国药理学和实验治疗学会 (ASPET)、英国药理学学会 (BPS) 和 Wiley 联合出版。PR&P 是一份双月刊的开放获取期刊，出版各种类型的文章，包括：靶标验证（表明假设不正确的临床前论文或关于在早期临床开发中失败的药物的论文）；药物发现评论（导致成功治疗药物的策略、假设和数据）；转化医学前沿（针对未满足的治疗需求的药物和靶标验证）；药理学假设（旨在为新假设提供信息的评论）；以及复制研究（反驳关键发现 [复制失败] 的工作和验证关键发现的工作）。PR&P 发表直接提交给期刊的论文以及 ASPET 和 BPS 期刊推荐的论文

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映General Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为2.9，平均审稿速度为 20 Weeks ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。